These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 12703356

  • 1. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10ng/ml].
    Poissonnier L, Gelet A, Chapelon JY, Bouvier R, Rouviere O, Pangaud C, Lyonnet D, Dubernard JM.
    Prog Urol; 2003 Feb; 13(1):60-72. PubMed ID: 12703356
    [Abstract] [Full Text] [Related]

  • 2. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.
    Blana A, Walter B, Rogenhofer S, Wieland WF.
    Urology; 2004 Feb; 63(2):297-300. PubMed ID: 14972475
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
    Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y.
    J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
    [Abstract] [Full Text] [Related]

  • 5. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
    Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A.
    Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Control of prostate cancer by transrectal HIFU in 227 patients.
    Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A.
    Eur Urol; 2007 Feb; 51(2):381-7. PubMed ID: 16857310
    [Abstract] [Full Text] [Related]

  • 10. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [Abstract] [Full Text] [Related]

  • 11. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study.
    Uchida T, Baba S, Irie A, Soh S, Masumori N, Tsukamoto T, Nakatsu H, Fujimoto H, Kakizoe T, Ueda T, Ichikawa T, Ohta N, Kitamura T, Sumitomo M, Hayakawa M, Aoyagi T, Tachibana M, Ikeda R, Suzuki K, Tsuru N, Suzuki K, Ozono S, Fujimoto K, Hirao Y, Monden K, Nasu Y, Kumon H, Nishi K, Ueda S, Koga H, Naitoh S.
    Hinyokika Kiyo; 2005 Oct; 51(10):651-8. PubMed ID: 16285617
    [Abstract] [Full Text] [Related]

  • 12. Treatment of localized prostate cancer using high-intensity focused ultrasound.
    Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A.
    BJU Int; 2006 Jan; 97(1):56-61. PubMed ID: 16336329
    [Abstract] [Full Text] [Related]

  • 13. Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy.
    Murota-Kawano A, Nakano M, Hongo S, Shoji S, Nagata Y, Uchida T.
    BJU Int; 2010 Jun; 105(12):1642-5. PubMed ID: 19922544
    [Abstract] [Full Text] [Related]

  • 14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 15. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D, Berger J, Gross AJ.
    BJU Int; 2012 Dec 01; 110(11):1702-7. PubMed ID: 22928703
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
    Uchida T, Illing RO, Cathcart PJ, Emberton M.
    BJU Int; 2006 Sep 01; 98(3):537-9. PubMed ID: 16925749
    [Abstract] [Full Text] [Related]

  • 18. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.
    Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A.
    Eur Urol; 2008 Jun 01; 53(6):1194-201. PubMed ID: 17997026
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.
    Urol Oncol; 2012 Sep 01; 30(5):577-83. PubMed ID: 21292508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.